share_log

D. Boral Capital Maintains Buy on NRX Pharmaceuticals, Maintains $31 Price Target

Benzinga ·  Mar 17 13:57

D. Boral Capital analyst Jason Kolbert maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $31 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 270

Recommended

Write a comment